Sugi Predict

Sugi Predict / Compounds / SCHEMBL514259

SCHEMBL514259

SCHEMBL514259

NC(=O)Cc1ccc(Br)cn1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADRA2A P08913 2/20 0.47
▸ ADRA2B P18089 2/20 0.47
▸ ADRA2C P18825 2/20 0.47
▸ PLAU P00749 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ FPR2 P25090 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GLS O94925 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GBA1 P04062 1/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ RAB9A P51151 2/20 0.37
▸ MBOAT4 Q96T53 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28126589 0.84 ALDH1A1 (0.48) ADRA2AADRA2BADRA2CPLAUALDH1A1
SCHEMBL5686 0.82 ALDH1A1 (0.52) ADRA2AADRA2BADRA2CPLAUALDH1A1
Acetamide SCHEMBL1257246 0.82 KDM4E (0.44) ADRA2AADRA2BADRA2CPLAUALDH1A1
SCHEMBL1257247 0.82 ADRA2A (0.39) ADRA2AADRA2BADRA2CPLAUALDH1A1
SCHEMBL29308626 0.81 FPR2 (0.45) ADRA2AADRA2BADRA2CPLAUALDH1A1
Hydrochloric Acid SCHEMBL3759897 0.81 ALDH1A1 (0.50) ADRA2AADRA2BADRA2CPLAUALDH1A1
SCHEMBL13754672 0.81 KDM4E (0.46) ADRA2AADRA2BADRA2CPLAUALDH1A1
SCHEMBL29474748 0.79 ALDH1A1 (0.48) ADRA2AADRA2BADRA2CPLAUALDH1A1
SCHEMBL27184068 0.79 ALDH1A1 (0.48) ADRA2AADRA2BADRA2CPLAUALDH1A1
SCHEMBL3624625 0.78 ADRA2A (0.46) ADRA2AADRA2BADRA2CSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 — — US disclosed
US-12257247-B2 Targeted degradation of VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-03-25 — — US disclosed
US-20240285604-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2024-08-29 — — US disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 — — WO disclosed
US-11737463-B2 Pyridine and pyrazine compounds BASF SE (DE) 2023-08-29 — — US disclosed
US-20210145002-A1 PYRIDINE AND PYRAZINE COMPOUNDS BASF SE (DE) 2021-05-20 — — US disclosed
WO-2020206583-A1 KINASE INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2020-10-15 — — WO disclosed
US-20130102605-A1 INHIBITORS OF AKT ACTIVITY LIANG PENG (CN) 2013-04-25 — — US disclosed
WO-2012135749-A2 BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS GENENTECH, INC. (US) 2012-10-04 — — WO disclosed
EP-2445909-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES Boehringer Ingelheim International GmbH (DE) 2012-05-02 — — EP disclosed
US-20120028918-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) 2012-02-02 — — US disclosed
CN-102341383-A Inhibitors of Bruton's Tyrosine Kinase HOFFMANN LA ROCHE 2012-02-01 — — CN disclosed
WO-2011130654-A1 FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY GENENTECH, INC. (US) 2011-10-20 — — WO disclosed
WO-2010141273-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-09 — — WO disclosed
EP-1924573-A1 B-RAF INHIBITORS AstraZeneca AB (SE) 2008-05-28 — — EP disclosed
WO-2006079791-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2006-08-03 — — WO disclosed
US-6794378-B2 ANTIINFLAMMATORY AGENTS AJINOMOTO CO., INC. (JP) 2004-09-21 — — US disclosed
US-20020133005-A1 Heterocyclic compounds and medical use thereof AJINOMOTO CO., INC. (JP) 2002-09-19 — — US disclosed
EP-1193255-A1 HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF Ajinomoto Co., Inc. (JP) 2002-04-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11737463-B2 Pyridine and pyrazine compounds NDUFS5, IL5, NDUFS4 ADRA2A 2930/4885ADRA2B 2641/4885ADRA2C 1607/4885
US-20210145002-A1 PYRIDINE AND PYRAZINE COMPOUNDS NDUFS5, IL5, NDUFS4 ADRA2A 2930/4885ADRA2B 2641/4885ADRA2C 1607/4885
US-20120028918-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME PIK3CA, G6PC1, PIK3C2B ADRA2A 2256/4885ADRA2B 1467/4885ADRA2C 2110/4885
US-20130102605-A1 INHIBITORS OF AKT ACTIVITY PIK3CA, PIK3CD, AKT2 ADRA2A 4465/4885ADRA2B 4396/4885ADRA2C 4049/4885
US-20240285604-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL ADRA2A 3731/4885ADRA2B 4004/4885ADRA2C 3773/4885
US-12257247-B2 Targeted degradation of VAV1 VAV1, KRAS, CBL ADRA2A 3731/4885ADRA2B 4004/4885ADRA2C 3773/4885
US-20020133005-A1 Heterocyclic compounds and medical use thereof NFKBIA, CHUK, RELA ADRA2A 3938/4885ADRA2B 3333/4885ADRA2C 3567/4885
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL ADRA2A 3731/4885ADRA2B 4004/4885ADRA2C 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.